⚠ The Growth Rate Is Set in WashingtonHigh threat

Intuitive Surgical (ISRG) — threat to the moat

The widest moat in medical devices, and its growth rate is set by whether an American with a hernia has insurance this year.

The most important sentence in Intuitive's 10-K is in the seasonality paragraph, where nobody looks: "More than half of da Vinci procedures performed are for benign conditions."1

What two points of procedure growth cost$207BMarket value,end 2025 ($B)$130BMarket value,Sept 2026 ($B)+19%Q2 revenue growth (%)+31%Q2 operatingincome growth (%)US procedure growth fell from 14% to 12%; the shares are $366.70 against a 52-week high of $603.88.
About $77 billion removed from a company whose June quarter was the best in its history. The market was not repricing the business; it was repricing the growth rate.

Benign means elective. Elective means postponable. And in 2026 a large number of American patients postponed. United States da Vinci procedure growth fell from 14% in the first quarter to 12% in the second, with the softening concentrated in the deferrable categories — hernia repair, cholecystectomy — while non-deferrable categories held2. Management attributed it to the expiry of enhanced Affordable Care Act premium subsidies, the chief financial officer saying they "had a modest adverse impact on U.S. da Vinci procedure volume in Q2". Full-year guidance for worldwide da Vinci procedure growth is 13.5% to 15.5% with an expectation of landing nearer the midpoint3, against 18% delivered in 2025 and 17% in 20244.

The market's reaction was disproportionate to the guidance and proportionate to what the guidance implies. The shares were $398.58 in late September 2026 against a 52-week high of $603.88, and market value has fallen from roughly $207 billion at the end of 2025 to about $141 billion5. Roughly $66 billion has been removed from a company whose June-quarter revenue grew 19% and operating income 31%.

Two things make this a structural threat rather than a bad quarter. The first is that it is not over: Medicaid work requirements are expected to take effect in 2027, and the coverage changes are policy rather than cycle. The second is Intuitive's own response. On the same call it announced an Extended Use Program that will raise the permitted number of uses on selected EndoWrist instruments in the first half of 2027, to "lower costs for benign procedures"6, and for the geographies where cost constraints are greatest — the razor-and-blade toll, loosened deliberately, to keep the deferrable half of the business happening. Asked directly whether product mix could offset the pricing headwind and keep instrument revenue per procedure flat in 2027 and 2028, the chief financial officer declined to say, offering instead: "When there is an opportunity to drive incremental growth by reducing customer costs through innovation, we are willing to do that."7

Management's case is that the disease burden has not changed and the procedures will eventually be performed. That is probably right in the long run and says nothing about the next two years.

The falsifier is specific and dated: United States da Vinci procedure growth. Two consecutive quarters below 12% while non-deferrable categories hold would mean this is not deferral but a lower structural growth rate, and everything about the multiple was built on the higher one.

The number that tests this threat
Reported
U.S. procedure growth, and what the market did with it
14% to 12% in one quarter; the shares 34% below their high

Roughly $66 billion of market value removed since the end of 2025 from a company whose June-quarter revenue grew 19% and operating income 31%. The threat is structural rather than cyclical because Medicaid work requirements are expected in 2027. Watch U.S. procedure growth in the deferrable categories — hernia and cholecystectomy — not the worldwide number.

The procedure growth figures are company-disclosed; the share price and market capitalisation are market data.
Source: Intuitive Surgical Q2 2026 earnings call and market data, September 2026 ↗
References
  1. ReportedThe most important sentence in Intuitive's 10-K is in the seasonality paragraph, where nobody looks: "More than half of da Vinci procedures performed are for benign conditions." Benign means elective.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  2. ReportedUnited States da Vinci procedure growth fell from 14% in the first quarter to 12% in the second, with the softening concentrated in the deferrable categories — hernia repair, cholecystectomy — while non-deferrable categories held.
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
  3. ReportedFull-year guidance for worldwide da Vinci procedure growth is 13.5% to 15.5% with an expectation of landing nearer the midpoint, against 18% delivered in 2025 and 17% in 2024.
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
  4. ReportedFull-year guidance for worldwide da Vinci procedure growth is 13.5% to 15.5% with an expectation of landing nearer the midpoint, against 18% delivered in 2025 and 17% in 2024.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, business and operating highlights (3,153,000 da Vinci procedures up 18%, 1,721 placements, an installed base of 11,106, utilisation up about 3%, 870 da Vinci 5 placements, Ion procedures and placements, procedures by region and category, and revenue denominated in foreign currencies) — FY2025 · publ. February 3, 2026 · source ↗
  5. ReportedThe shares were $398.58 in late September 2026 against a 52-week high of $603.88, and market value has fallen from roughly $207 billion at the end of 2025 to about $141 billion.
    Intuitive Surgical (NASDAQ: ISRG) market data, 23 September 2026 - $398.58 a share, market capitalisation $140.81 billion on 353.28 million shares, P/E 46.11, forward P/E 35.59; 52-week high $603.88 (companiesmarketcap: $142.84 billion) — September 2026 · publ. 2026-09-23 · source ↗
  6. ReportedOn the same call it announced an Extended Use Program that will raise the permitted number of uses on selected EndoWrist instruments in the first half of 2027, "designed to reduce customer costs in benign procedures and cost-constrained...
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
  7. ReportedAsked directly whether product mix could offset the pricing headwind and keep instrument revenue per procedure flat in 2027 and 2028, the chief financial officer declined to say, offering instead: "When there is an opportunity to drive...
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
Sources
Generated September 23, 2026